Systematic	O
variation	O
of	O
the	O
benzenesulfonamide	B:C0053169
part	O
of	O
the	O
GluN2A	O
selective	I:C1530202
NMDA	I:C1530202
receptor	I:C1530202
antagonist	O
TCN	O
-	I:C3494094
201	I:C3494094
.	O

Systematic	O
variation	O
of	O
the	O
benzenesulfonamide	O
part	O
of	O
the	O
GluN2A	B:C1530202
selective	I:C1530202
NMDA	I:C1530202
receptor	I:C1530202
antagonist	O
TCN	O
-	I:C3494094
201	I:C3494094
.	O

Systematic	O
variation	O
of	O
the	O
benzenesulfonamide	O
part	O
of	O
the	O
GluN2A	O
selective	I:C1530202
NMDA	I:C1530202
receptor	I:C1530202
antagonist	B:C0003139
TCN	O
-	I:C3494094
201	I:C3494094
.	O

Systematic	O
variation	O
of	O
the	O
benzenesulfonamide	O
part	O
of	O
the	O
GluN2A	O
selective	I:C1530202
NMDA	I:C1530202
receptor	I:C1530202
antagonist	O
TCN	B:C3494094
-	I:C3494094
201	I:C3494094
.	O

GluN2A	B:C1530202
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
(	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
)	O
are	O
highly	O
involved	O
in	O
various	O
physiological	O
processes	I:C0031845
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
,	O
but	O
also	O
in	O
some	O
diseases	O
,	O
such	O
as	O
anxiety	O
,	O
depression	O
and	O
schizophrenia	O
.	O

GluN2A	O
subunit	I:C1530202
containing	O
N	B:C0080093
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
(	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
)	O
are	O
highly	O
involved	O
in	O
various	O
physiological	O
processes	I:C0031845
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
,	O
but	O
also	O
in	O
some	O
diseases	O
,	O
such	O
as	O
anxiety	O
,	O
depression	O
and	O
schizophrenia	O
.	O

GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
(	O
N	B:C0080093
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
)	O
are	O
highly	O
involved	O
in	O
various	O
physiological	O
processes	I:C0031845
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
,	O
but	O
also	O
in	O
some	O
diseases	O
,	O
such	O
as	O
anxiety	O
,	O
depression	O
and	O
schizophrenia	O
.	O

GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
(	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
)	O
are	O
highly	O
involved	O
in	O
various	O
physiological	B:C0031845
processes	I:C0031845
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
,	O
but	O
also	O
in	O
some	O
diseases	O
,	O
such	O
as	O
anxiety	O
,	O
depression	O
and	O
schizophrenia	O
.	O

GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
(	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
)	O
are	O
highly	O
involved	O
in	O
various	O
physiological	O
processes	I:C0031845
in	O
the	O
central	B:C3714787
nervous	I:C3714787
system	I:C3714787
,	O
but	O
also	O
in	O
some	O
diseases	O
,	O
such	O
as	O
anxiety	O
,	O
depression	O
and	O
schizophrenia	O
.	O

GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
(	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
)	O
are	O
highly	O
involved	O
in	O
various	O
physiological	O
processes	I:C0031845
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
,	O
but	O
also	O
in	O
some	O
diseases	B:C0012634
,	O
such	O
as	O
anxiety	O
,	O
depression	O
and	O
schizophrenia	O
.	O

GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
(	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
)	O
are	O
highly	O
involved	O
in	O
various	O
physiological	O
processes	I:C0031845
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
,	O
but	O
also	O
in	O
some	O
diseases	O
,	O
such	O
as	O
anxiety	B:C0003467
,	O
depression	O
and	O
schizophrenia	O
.	O

GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
(	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
)	O
are	O
highly	O
involved	O
in	O
various	O
physiological	O
processes	I:C0031845
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
,	O
but	O
also	O
in	O
some	O
diseases	O
,	O
such	O
as	O
anxiety	O
,	O
depression	B:C0011570
and	O
schizophrenia	O
.	O

GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
(	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
)	O
are	O
highly	O
involved	O
in	O
various	O
physiological	O
processes	I:C0031845
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
,	O
but	O
also	O
in	O
some	O
diseases	O
,	O
such	O
as	O
anxiety	O
,	O
depression	O
and	O
schizophrenia	B:C0036341
.	O

However	O
,	O
the	O
role	O
of	O
GluN2A	B:C1530202
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
in	O
pathological	O
processes	I:C0030660
is	O
not	O
exactly	O
elucidated	O
.	O

However	O
,	O
the	O
role	O
of	O
GluN2A	O
subunit	I:C1530202
containing	O
N	B:C0080093
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
in	O
pathological	O
processes	I:C0030660
is	O
not	O
exactly	O
elucidated	O
.	O

However	O
,	O
the	O
role	O
of	O
GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
in	O
pathological	B:C0030660
processes	I:C0030660
is	O
not	O
exactly	O
elucidated	O
.	O

In	O
order	O
to	O
obtain	O
potent	O
and	O
selective	O
inhibitors	B:C0243077
of	O
GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
,	O
the	O
selective	O
negative	O
allosteric	I:C1254351
modulator	I:C1254351
2	I:C1254351
was	O
systematically	O
modified	O
at	O
the	O
benzenesulfonamide	O
part	O
.	O

In	O
order	O
to	O
obtain	O
potent	O
and	O
selective	O
inhibitors	O
of	O
GluN2A	B:C1530202
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
,	O
the	O
selective	O
negative	O
allosteric	I:C1254351
modulator	I:C1254351
2	I:C1254351
was	O
systematically	O
modified	O
at	O
the	O
benzenesulfonamide	O
part	O
.	O

In	O
order	O
to	O
obtain	O
potent	O
and	O
selective	O
inhibitors	O
of	O
GluN2A	O
subunit	I:C1530202
containing	O
N	B:C0080093
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
,	O
the	O
selective	O
negative	O
allosteric	I:C1254351
modulator	I:C1254351
2	I:C1254351
was	O
systematically	O
modified	O
at	O
the	O
benzenesulfonamide	O
part	O
.	O

In	O
order	O
to	O
obtain	O
potent	O
and	O
selective	O
inhibitors	O
of	O
GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
,	O
the	O
selective	O
negative	B:C1254351
allosteric	I:C1254351
modulator	I:C1254351
2	I:C1254351
was	O
systematically	O
modified	O
at	O
the	O
benzenesulfonamide	O
part	O
.	O

In	O
order	O
to	O
obtain	O
potent	O
and	O
selective	O
inhibitors	O
of	O
GluN2A	O
subunit	I:C1530202
containing	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
,	O
the	O
selective	O
negative	O
allosteric	I:C1254351
modulator	I:C1254351
2	I:C1254351
was	O
systematically	O
modified	O
at	O
the	O
benzenesulfonamide	B:C0053169
part	O
.	O

The	O
activity	O
of	O
the	O
test	O
compounds	B:C1706082
was	O
recorded	O
in	O
two	O
electrode	I:C0242623
voltage	I:C0242623
clamp	I:C0242623
experiments	I:C0242623
using	O
Xenopus	O
laevis	I:C0043343
oocytes	O
expressing	O
exclusively	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
with	O
GluN1a	O
and	O
GluN2A	O
subunits	I:C1530202
.	O

The	O
activity	O
of	O
the	O
test	O
compounds	O
was	O
recorded	B:C1301725
in	O
two	O
electrode	I:C0242623
voltage	I:C0242623
clamp	I:C0242623
experiments	I:C0242623
using	O
Xenopus	O
laevis	I:C0043343
oocytes	O
expressing	O
exclusively	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
with	O
GluN1a	O
and	O
GluN2A	O
subunits	I:C1530202
.	O

The	O
activity	O
of	O
the	O
test	O
compounds	O
was	O
recorded	O
in	O
two	B:C0242623
electrode	I:C0242623
voltage	I:C0242623
clamp	I:C0242623
experiments	I:C0242623
using	O
Xenopus	O
laevis	I:C0043343
oocytes	O
expressing	O
exclusively	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
with	O
GluN1a	O
and	O
GluN2A	O
subunits	I:C1530202
.	O

The	O
activity	O
of	O
the	O
test	O
compounds	O
was	O
recorded	O
in	O
two	O
electrode	I:C0242623
voltage	I:C0242623
clamp	I:C0242623
experiments	I:C0242623
using	O
Xenopus	B:C0043343
laevis	I:C0043343
oocytes	O
expressing	O
exclusively	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
with	O
GluN1a	O
and	O
GluN2A	O
subunits	I:C1530202
.	O

The	O
activity	O
of	O
the	O
test	O
compounds	O
was	O
recorded	O
in	O
two	O
electrode	I:C0242623
voltage	I:C0242623
clamp	I:C0242623
experiments	I:C0242623
using	O
Xenopus	O
laevis	I:C0043343
oocytes	B:C0029045
expressing	O
exclusively	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
with	O
GluN1a	O
and	O
GluN2A	O
subunits	I:C1530202
.	O

The	O
activity	O
of	O
the	O
test	O
compounds	O
was	O
recorded	O
in	O
two	O
electrode	I:C0242623
voltage	I:C0242623
clamp	I:C0242623
experiments	I:C0242623
using	O
Xenopus	O
laevis	I:C0043343
oocytes	O
expressing	O
exclusively	O
N	B:C0080093
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
with	O
GluN1a	O
and	O
GluN2A	O
subunits	I:C1530202
.	O

The	O
activity	O
of	O
the	O
test	O
compounds	O
was	O
recorded	O
in	O
two	O
electrode	I:C0242623
voltage	I:C0242623
clamp	I:C0242623
experiments	I:C0242623
using	O
Xenopus	O
laevis	I:C0043343
oocytes	O
expressing	O
exclusively	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
with	O
GluN1a	B:C0080093
and	O
GluN2A	O
subunits	I:C1530202
.	O

The	O
activity	O
of	O
the	O
test	O
compounds	O
was	O
recorded	O
in	O
two	O
electrode	I:C0242623
voltage	I:C0242623
clamp	I:C0242623
experiments	I:C0242623
using	O
Xenopus	O
laevis	I:C0043343
oocytes	O
expressing	O
exclusively	O
N	O
-	I:C0080093
methyl	I:C0080093
-	I:C0080093
d	I:C0080093
-	I:C0080093
aspartate	I:C0080093
receptors	I:C0080093
with	O
GluN1a	O
and	O
GluN2A	B:C1530202
subunits	I:C1530202
.	O

It	O
was	O
found	O
that	O
halogen	O
atoms	O
in	O
3	O
-	O
position	O
of	O
the	O
benzenesulfonamide	B:C0053169
part	O
result	O
in	O
high	O
GluN2A	O
antagonistic	O
activity	I:C0243095
.	O

It	O
was	O
found	O
that	O
halogen	O
atoms	O
in	O
3	O
-	O
position	O
of	O
the	O
benzenesulfonamide	O
part	O
result	O
in	O
high	O
GluN2A	B:C1530202
antagonistic	O
activity	I:C0243095
.	O

It	O
was	O
found	O
that	O
halogen	O
atoms	O
in	O
3	O
-	O
position	O
of	O
the	O
benzenesulfonamide	O
part	O
result	O
in	O
high	O
GluN2A	O
antagonistic	B:C0243095
activity	I:C0243095
.	O

With	O
an	O
IC50	O
value	O
of	O
204	O
nM	O
the	O
3	B:C1254351
-	I:C1254351
bromo	I:C1254351
derivative	I:C1254351
5i	I:C1254351
(	I:C1254351
N-{4-[(2-benzoylhydrazino	I:C1254351
)	I:C1254351
carbonyl]	I:C1254351
benzyl}-3-bromobenzenesulfonamide	I:C1254351
)	I:C1254351
has	O
2.5	O
-	O
fold	O
higher	O
antagonistic	O
activity	I:C0243095
than	O
the	O
lead	O
compound	I:C1254351
2	I:C1254351
and	O
represents	O
our	O
new	O
lead	O
compound	O
.	O

With	O
an	O
IC50	O
value	O
of	O
204	O
nM	O
the	O
3	O
-	I:C1254351
bromo	I:C1254351
derivative	I:C1254351
5i	I:C1254351
(	I:C1254351
N-{4-[(2-benzoylhydrazino	I:C1254351
)	I:C1254351
carbonyl]	I:C1254351
benzyl}-3-bromobenzenesulfonamide	I:C1254351
)	I:C1254351
has	O
2.5	O
-	O
fold	O
higher	O
antagonistic	B:C0243095
activity	I:C0243095
than	O
the	O
lead	O
compound	I:C1254351
2	I:C1254351
and	O
represents	O
our	O
new	O
lead	O
compound	O
.	O

With	O
an	O
IC50	O
value	O
of	O
204	O
nM	O
the	O
3	O
-	I:C1254351
bromo	I:C1254351
derivative	I:C1254351
5i	I:C1254351
(	I:C1254351
N-{4-[(2-benzoylhydrazino	I:C1254351
)	I:C1254351
carbonyl]	I:C1254351
benzyl}-3-bromobenzenesulfonamide	I:C1254351
)	I:C1254351
has	O
2.5	O
-	O
fold	O
higher	O
antagonistic	O
activity	I:C0243095
than	O
the	O
lead	B:C1254351
compound	I:C1254351
2	I:C1254351
and	O
represents	O
our	O
new	O
lead	O
compound	O
.	O

